ECMO, DEFINITION, ETIOLOGY, INDICATION, CONTRAINDICATION, TYPES OF ECMO, VENOVENOUS ECMO, VENO ARTERIAL ECMO, NURSING CARE OF PATIENT ON ECMO, WEANING FROM ECMO,
Comprehensive presentation on intra arterial blood pressure with a good insight into the the basic physics and brief look into the risks and complications.
Cardiopulmonary bypass development and history
Indication of cpb
Hardware in cpb
Arterial and venous cannulation
Oxygenator
Heat exchanger
Filter
How to conduct cpb and problems in cpb
Cardioplegia
An excellent tool to treat refractory hypoxia. Target audience are ICU junior physicians and Respiratory Therapists. It will take away the fear of "What is APRV?" from your hearts and you will feel ready to give it a try.
Comprehensive presentation on intra arterial blood pressure with a good insight into the the basic physics and brief look into the risks and complications.
Cardiopulmonary bypass development and history
Indication of cpb
Hardware in cpb
Arterial and venous cannulation
Oxygenator
Heat exchanger
Filter
How to conduct cpb and problems in cpb
Cardioplegia
An excellent tool to treat refractory hypoxia. Target audience are ICU junior physicians and Respiratory Therapists. It will take away the fear of "What is APRV?" from your hearts and you will feel ready to give it a try.
PowerPoint presentation on ECMO (Extracorporeal Membrane Oxygenation). Part 2 focuses on Monitoring ECMO patients
Ventilatory strategies, Sedation and pain control, Weaning, Complications and recent advances in ECMO. For better understanding please have a look at ECMO part 1 before going through part 2.
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Mesa redonda: Insuficiencia cardiaca aguda
VIERNES, 17 DE JUNIO 09:15-10:30 SALA A
¿En qué circunstancias debemos utilizar dispositivos mecánicos y cuáles son los más indicados?
José González Costelo, Barcelona
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Asistencia ventricular de larga duración: Cómo estamos y cómo deberíamos organizarnos
VIERNES, 17 DE JUNIO 15:15-16:30 SALÓN DE ACTOS
Cirugía mínimamente invasiva para el implante de asistencia ventricular izquierda en pacientes con terapia de destino
Sebastián Rojas, Hannover. Alemania
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Asistencia ventricular de larga duración: Cómo estamos y cómo deberíamos organizarnos
VIERNES, 17 DE JUNIO 15:15-16:30 SALÓN DE ACTOS
Realidad en España. Organización de un programa de asistencia ventricular
Manuel Gómez Bueno, Madrid
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Asistencia ventricular de larga duración: Cómo estamos y cómo deberíamos organizarnos
VIERNES, 17 DE JUNIO 15:15-16:30 SALÓN DE ACTOS
Papel de la Enfermería en el seguimiento de pacientes con asistencia mecánica
Leticia Jimeno San Martín, Pamplona
Veno-Arterial Ecmo (VA-ECMO) & Their basicGunalan M.M
VA ECMO stands for Venoarterial Extracorporeal Membrane Oxygenation. It's a life-saving medical procedure used in critical situations where the heart and lungs are unable to function adequately. VA ECMO involves diverting blood from the body, oxygenating it outside the body, and then returning it to the arterial system, effectively bypassing the heart and lungs. This allows time for the organs to rest and heal, supporting patients with severe cardiac or respiratory failure.
Short term MCS as the parachute... non RCTs in support... but try to launch out of the plane without it ;-)
Slides from the first hospital meeting On the use of MCS systems.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
2. When I think about Ecmo, I think …
AVELIN D'SOUZA
3. Introduction
ECMO is instituted for the management of life
threatening pulmonary or cardiac failure (or both),
when no other form of treatment has been or is likely
to be successful.
ECMO is essentially a modification of the
cardiopulmonary bypass circuit which is used
routinely in cardiac surgery.
AVELIN D'SOUZA
4. Introduction
Instituted in an emergency or urgent situation after
failure of other treatment modalities.
It is used as temporary support, usually awaiting
recovery of organs.
AVELIN D'SOUZA
5. History
In 1965, Rashkind and coworkers were the first to
use a bubble oxygenator as support in a neonate
dying of respiratory failure. In 1969, Dorson and
colleagues reported the use of a membrane
oxygenator for cardiopulmonary bypass in infants.
In 1970, Baffes et al reported the successful use of
extracorporeal membrane oxygenation as support in
infants with congenital heart defects who were
undergoing cardiac surgery. In 1975, Bartlett et al
were the first to successfully use ECMO in neonates
with severe respiratory distress.
AVELIN D'SOUZA
7. Definition
ECMO or Extra Corporeal Membrane Oxygenation
is a form of extracorporeal life support where an
external artificial circuit carries venous blood from
the patient to a gas exchange device (oxygenator)
where blood becomes enriched with oxygen and
has carbon dioxide removed. This blood then
reenters the patient circulation.
ECMO circuit blood flow is optimised to provide
adequate patient support in the absence of native
lung or heart function.
AVELIN D'SOUZA
9. The Mode of ECMO is defined by the position of the
access and return cannulae.
There are three modes of ECMO:
Veno-Venous (VV)
Veno-Arterial (VA) and
Veno-Pulmonary Artery (V-PA)
VV and VA modes of ECMO have a number of
configurations to best suit patient needs.
AVELIN D'SOUZA
10. Veno-arterial (VA) configuration
Blood being drained from the venous system and returned to
the arterial system.
Provides both cardiac and respiratory support.
Achieved by either peripheral or central cannulation
AVELIN D'SOUZA
12. Veno-Venous (VV) configuration
Provides oxygenation
Blood being drained from venous system and returned to
venous system.
Only provides respiratory support
Achieved by peripheral cannulation, usually of both femoral
veins.
AVELIN D'SOUZA
13. a. Veno-Venous ECMO:
Venous blood is accessed from the large central veins,
pumped through the oxygenator and returned to the venous
system near the right atrium. It provides support for severe
respiratory failure.
There are 4 configurations of VV ECMO
i. Femoro-Femoral (Fem/Fem)
ii. High-Flow
iii. Femoro-Jugular
iv. Dual lumen/Two stage single cannula (Avalon)
In all cases, ECMO blood flow travels from the vena cavae to
the atria (Cavo-Atrial Flow) to minimise recirculationAVELIN D'SOUZA
14. a.Femoro-Femoral:
i. Two long “venous” cannulae are used
ii. Direction of flow is cavo-atrial
iii. Access cannula (single stage, or multistage) is inserted via the femoral
vein. Usual sizes 21-25 F
iv. Return cannula (single stage) is inserted via the contralateral femoral
vein with the tip sited within the right atrium. If the tip is advanced too
far it will impinge on the inter-atrial septum.
Usual sizes 21-25 F
v. The tip of the access cannula is positioned 10-15cm lower than the tip
of the return cannula to minimise recirculation.
Advantages: Quick and safe to insert; easy to secure cannulae;
Disadvantages:
Limited maximum flow rates so often requires conversion to a high-flow
configuration. Patient remains bed bound
AVELIN D'SOUZA
16. b. High-flow:
i. Uses the same bi-femoral cannulation as femoro-femoral
ii. An additional short access cannula (“arterial”) is inserted via the right
internal jugular vein with the tip sited in the superior vena cava. The
optimal position of the tip is established after commencing full circuit
blood flow. The tip is withdrawn sufficiently to prevent visible
recirculation. Usual size 17-19 F
iii. Direction of flow is bi-cavo-atrial to minimise recirculation
Advantages:
Allows higher circuit blood flows as two access cannulae draw patient
blood from the great veins .
Can provide maximal oxygen delivery if configured correctly
Disadvantages: Occupies 3 veins. Relatively complex to secure and
dress the jugular
cannula. Patient remains bed bound.
AVELIN D'SOUZA
17. c. Femoro-Jugular:
i. Direction of flow is cavo-atrial to minimise recirculation
ii. Access cannula (multi-stage) is inserted via the femoral vein with the
tip sited just below the inferior cavo-atrial junction. Usual size 21-25 F
iii. Return short cannula (“arterial”) is inserted into the right internal
jugular vein with the tip sited in the lower superior vena cava. Blood
returning in this direction preferentially flows towards the tricuspid valve
and right ventricle, which minimises recirculation. Usual sizes 19-23 F
iv. Advantages: Nearly always can provide adequate support (5-7 L/min)
without large recirculation, only two veins occupied
Disadvantages: Relatively difficult to secure and dress the jugular return
cannula. Requires two sterile fields to be during ECMO cannulation.
Access insufficiency can be more difficult to identifyin the early stages
without negative pressure monitoring Patient remains bed bound
AVELIN D'SOUZA
18. d. Dual lumen/Two stage single cannula (Avalon):
i. Direction of flow is bi-cavo-atrial to minimise recirculation
ii. Single cannula with two lumens for access and return inserted via the
right internal Jugular vein.
iii. Two access stages (SVC and IVC)
iv. Return port emerges between the two access ports and is positioned at
the level of the tricuspid valve.
Advantages: Single vein cannulation. Allows movement from bed and
potentially ambulation
Disadvantages: Care on insertion to avoid right ventricular
placement/rupture and hepatic vein cannulation.Large cannula to insert
(27F or 31F for adults). Difficult to position return port towards the
tricuspid valve.
AVELIN D'SOUZA
20. a. Standard Femoro-Femoral
i. Access Cannula (multistage) is inserted via the femoral vein
with the tip sited within the right atriumwithout impinging
on the interatrial septum.
Usual size 21-25 F
ii. Return cannula is a short arterial cannula inserted via the
common femoral artery. Usual size 17-21 F
Advantages: Provides full or partial cardiac support.
Disadvantages: Risk of differential hypoxia may need
conversion to high flow configuration if native cardiac
function improves in the setting of significant respiratory
failure
AVELIN D'SOUZA
21. Central: Specialised cannulae
i. Uses specialised surgical cannulae. Access cannula is wire reinforced and
malleable and is sited within the right atrium via the atrial appendage. Cannula is
then tunnelled out of the chest and t he sternum closed. Usual size >30 F
ii. Return cannula is Dacron tipped and sewn directly onto the proximal aorta.
Cannula is then tunnelled out of the chest and the sternum closed. Usual size >30
F
iii. Advantages: Can provide full cardiac and respiratory support and is not
associated with differential hypoxia in the setting of combined cardiac and
respiratory failure. Optimal support for severe cardiac and respiratory failure in
the immediate post cardiotomy setting.
Allows sternum to be closed and facilitates standard patient pressure area care.
Can provide support for upto 2 weeks
iv.Disadvantages Requires sternotomy for institution and re-sternotomy for
decannulation. Bleedingmore common than in femoro-femoral configuration
AVELIN D'SOUZA
24. Central vs. Peripheral Cannulation
Advantages
Flow from Central ECMO is directly from the outflow cannula
into the aorta provides antegrade flow to the arch vessels,
coronaries and the rest of the body
In contrast, the retrograde aortic flow provided by peripheral
leads to mixing in the arch.
AVELIN D'SOUZA
25. Disadvantages
Previously insertion of central ECMO required leaving chest
open to allow the cannulae to exit.
Increased the risk of bleeding and infection
Newer cannulae are designed to be tunneled through the subcostal
abdominal wall allowing the chest to be completely closed.
Central cannula are costly (approximately 4 times as much as
peripheral)
AVELIN D'SOUZA
26. The Configuration of ECMO refers to the cannula insertion
site, type, tip position and size used in a particular mode.
Cannulae Definitions:
Access Cannulae: drain blood from the venous system
into the ECMO circuit.
Single stage access cannulae drain blood via a short region
near the tip only
Multi-stage access cannulae drain blood through side holes
over a long length of the cannula in addition to the tip.
AVELIN D'SOUZA
28. b) Return Cannulae: deliver blood back to the patient
from the ECMO circuit and only ever expel blood at
the cannula tip (single stage).
c) Distal Perfusion Cannula: Deliver blood
antegradely into the femoral artery distal to the
ECMO return cannula to maintain perfusion to the
leg.
d) d. Double-lumen Cannulae single cannula
partitioned into two lumens with both access blood
flow and return blood flow, similar to vascular
access cannulae used in renal replacement therapy.
AVELIN D'SOUZA
29. e) Cannula Length
i. Long cannulae (55 cm) are labelled by manufacturers
as “venous” and are designed for use in the venous
system.
ii. Short cannulae (15-25cm) are labelled by
manufacturers as “arterial”. They are used to return
blood in both VA ECMO and some VV ECMO
configurations
AVELIN D'SOUZA
30. Dynamics of ECMO
Blood is removed from the venous system either
peripherally via cannulation of a femoral vein or
centrally via cannulation of the right atrium,
Oxygenate
Extract carbon dioxide
Blood is then returned back to the body either
peripherally via a femoral artery or centrally via the
ascending aorta.
AVELIN D'SOUZA
32. Indications – Cardiac Failure
Post-cardiotomy
when unable to get pt off cardiopulmonary bypass following
cardiac surgery
Post-heart transplant
usually due to primary graft failure
Severe cardiac failure due to almost any other cause
Decompensated cardiomyopathy
Myocarditis
Acute coronary syndrome with cardiogenic shock
Profound cardiac depression due to drug overdose or sepsis
AVELIN D'SOUZA
33. Indications – Respiratory Failure
Adult respiratory distress syndrome (ARDS)
Pneumonia
Trauma
Primary graft failure following lung transplantation.
ECMO is also used for neonatal and pediatric
respiratory support
This is where most of the research on ECMO has been done
AVELIN D'SOUZA
34. Decision to Institute ECMO
Several considerations must be weighed:
Likelihood of organ recovery.: only appropriate if disease process is
reversible with therapy and rest on ECMO
Cardiac recovery: to either wait for further cardiac recovery to allow
implant of device (LVAD) or to list for transplantation.
Disseminated malignancy
Advanced age
Graft vs. host disease
Known severe brain injury
Unwitnessed cardiac arrest or cardiac arrest of prolonged duration.
Technical contraindications to consider: aortic dissection or aortic
incompetence
AVELIN D'SOUZA
37. Things to Think About
Mechanical ventilation must be continued during ECMO
support to try to maintain oxygen saturation of blood
ejected from the left ventricle to at least above 90%.
ECMO flow can be very volume dependent
ECMO flow will drop:
Hypovolemia
Cannula malposition
Pneumothorax
Pericardial tamponade.
AVELIN D'SOUZA
38. Weaning of ECMO – VV ECMO
Actual ECMO flows do not need to be altered to assess
native respiratory function
Done by altering gas flow through the ECMO circuit
Pt may be weanable:
Gas exchange is able to be maintained with a low FiO2 (<30%)
Low fresh gas flow rates into the circuit (<2 L/min)
Caveat: RR and PEEP set on ventilator are not too high
(e.g. <25 breaths/min and <15cmH2O, respectively).
AVELIN D'SOUZA
39. Weaning of ECMO – VA ECMO
Depends on cardiac recovery, Factors:
Increasing blood pressure
Return or increasing pulsatility on the arterial pressure waveform
Falling pO2 by a right radial arterial line
indicating more blood is being pumped through the heart which may
be less well oxygenated,
Falling central venous and/or pulmonary pressures.
It is important to note that cardiac outputs from
pulmonary artery catheter are inaccurate on ECMO
Most of the circulating blood volume is bypassing the pulmonary
circulation
AVELIN D'SOUZA
40. Complications
Falls into one of three major categories
1) Bleeding associated with heparinization
2) technical failure
3) neurologic sequelae
AVELIN D'SOUZA
41. Complications of ECMO
Bleeding/Hemolysis
Out of proportion to the degree of coagulopathy and patient
platelet count
Coagulopathy
Continuous activation of contact and fibrinolytic systems by the
circuit
Consumption and dilution of factors within minutes of initiation
of ECMO
AVELIN D'SOUZA
42. Complications of ECMO
Thrombocytopenia
Platelets adhere to surface fibrinogen and are activated
Resultant platelet aggregation and clumping causes numbers to
drop
Non-pulsatile perfusion to end organs
Kidneys
Splanchnic circulation seems to be particularly susceptible
GI bleeding, ulceration and perforation
Liver impairment
AVELIN D'SOUZA
43. Complications of ECMO
Mechanical Complications
Tubing rupture
Pump malfunction
Cannula related problems
Local complications: Leg ischemia
Particularly at peripheral insertion site of VA
Air embolism/Thromboembolism
Neurological: Intracerebral bleeds
Largely associated with sepsis
Manifest as seizures or brain death
AVELIN D'SOUZA
44. Management of Complications
Regular measurements of blood tests (Q6-Q8h)
Coagulation Profile
Platelet Count
Hemoglobin
Creatinine to evaluate for renal insufficiency
Aggressive replacement of clotting factors,
electrolytes, PRBC
AVELIN D'SOUZA
45. Outcomes of ECMO
Good quality RCT of ECMO outcomes in adult
population are lacking
There are very promising studies in the Pediatric
populations, however it is hard to know if this
translates into the adult population.
Completed yet unpublished CESAR Trial shows
some potential impact in ECMO research
AVELIN D'SOUZA
46. ECMO Observations and Documentation
Distal Perfusion (“Backflow”) cannula and leg vascular
observations must also be performed each hour for patients
on peripheral VA ECMO. In the event that blood flow through
the distal perfusion circuit is occluded, blood within the back
flow tubing will separate into plasma and cells, which is
obvious on inspection. Normal blood flow can be seen under
torchlight.
AVELIN D'SOUZA
47. ECMO dressings and line position
monitoring
The bedside nurse is responsible for maintaining cannula
dressings and redressing soiled or inadequate dressings.
Line position monitoring is performed at least once per shift
for patients with peripheral cannulae skin markings.
Pressure area care:
Patient Arterial Blood Gas (ABG)
Ensure that heater water level is approximately 75-80% full
Routine Investigations: CXR, Mg; PO4; LFT; APTT, INR,
Fibrinogen and D-dimers
AVELIN D'SOUZA
48. APTT is measured 6 hourly while the patient is on
ECMO if they are receiving systemic anticoagulation.
Peripheral VA ECMO patients require vascular
ultrasound studies to be performed on lower limbs
on day 1 and additionally as clinically indicated.
For VV ECMO target blood flows must provide
adequate arterial oxygenation while allowing non-
injurious lung ventilation.
Anticoagulation and prevention of bleeding.
AVELIN D'SOUZA
49. All ECMO lines must be secured at 2 points with
properly adherent skin dressings.
Sterility must be maintained and insertion sites kept
unsoiled.
A designated staff member must secure ECMO
circuit lines to prevent tension or torsion during
patient moves.
Do not allow water to enter the ECMO drive unit
Alcohol Containing Cleaning solutions (including
triclosan) should not come in to contact with the
ECMO circuit as they may cause cracking of some
circuit componentsAVELIN D'SOUZA
50. WEANING
VV ECMO weaning:
i. Circuit flow need not be reduced at any stage for weaning
and therefore, no additional heparin is required
ii. Weaning VV ECMO is achieved by progressively reducing
the Fresh Gas Flow to the oxygenator. An increase in lung
ventilation is required to ensure adequate CO2 clearance.
iii. In normal circumstances there is no requirement to wean
the blender FiO2 as part of the weaning process
iv. It is usual to observe the patient to be stable for 4-24 hours
with the Fresh Gas Flow to the ECMO circuit at 0 L/min .
v. Echocardiography is not required
AVELIN D'SOUZA
51. VA ECMO weaning:
Formal weaning studies must be performed to assess the heart’s ability to
manage the circulation without VA ECMO support. Circuit flow must be
reduced to assess native heart function in the setting of an increased
venous return. Flow is reduced from 2.5 L/min in a series of 0.5 L/min
increments while haemodynamic and echocardiographic data are
collected
ii. Lung ventilation must be increased and oxygenator Fresh Gas Flow
reduced during the weaning study
iii. The reduced flow during the VA weaning process increases the risk of
stasis and clotting within the circuit. Additional heparin is required to
reduce the risk of clotting in this setting
iv. Echocardiography is essential to assessing cardiac function during
weaning from ECMO
v. Once cardiac function has improved and ECMO decannulation is
planned, ECMO flows should be maintained above 2.5L until
decannulation takes place.AVELIN D'SOUZA
52. Cannula Removal and Circuit Disposal
Cannula Removal: Heparin should be ceased for at least 2
hours prior to decannulation. The patient should be
adequately sedated or have received an explanation of the
procedure prior to commencement. After dressings are
removed, all access and return lines are clamped, the ECMO
console powered off and the cannulae removed
simultaneously with immediate adequate pressure applied to
the vessel puncture sites with sterile gauze.
Returning the blood held within the ECMO circuit to the
patient prior to cannula removal carries additional risk of air
and thrombus entering the patient’s circulation and volume
overload. It should only be performed if there is a clinical
imperative to conserve blood.
AVELIN D'SOUZA
53. Cannula Removal and Circuit Disposal
Bleeding control: After percutaneously placed venous
cannulae are removed the venous puncture site is
compressed for 20 minutes by ECMO trained medical staff.
The patient must remain supine and still for approximately 4
hours post cannula removal and the site monitored for re-
bleeding
d.
Circuit disposal: The circuit should be disposed of in a
biohazard bag/bin with cytotoxic precautions where
appropriate. Reusable (metal) ECMO Clamps MUST not be
discarded.
AVELIN D'SOUZA
54. Summary
ECMO is instituted for the management of life
threatening pulmonary or cardiac failure (or both),
when no other form of treatment has been or is likely
to be successful.
ECMO is essentially a modification of the
cardiopulmonary bypass circuit which is used
routinely in cardiac surgery.
ECMO can be inserted in 2 configurations: Veno-
venous & Veno-arterial
Completed yet unpublished CESAR Trial shows
some potential impact in ECMO research
AVELIN D'SOUZA